Single-tablet pioglitazone combination filed in Japan
This article was originally published in Scrip
Takedahas filed an approval submission in Japan for a single-tablet combination of pioglitazone and metformin. The product stands to become the first fixed dose combination for type 2 diabetes in Japan, where pioglitazone, a thiazolidinedione, is already marketed alone as Actos. The single-tablet combination was approved as Actoplus met in the US this August and approved in the EU (as Competact) in July 2007. Japanese filings for Actos as concomitant therapy with either metformin or insulin were made in January and June respectively last year.